BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Treatment with both compounds has been shown to result in significant loss of CML stem cells, a result that cannot be achieved by the use of imatinib alone since CML stem cells do not require BCR-ABL to replicate [13,14,15].